Barclays Boosts Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $9.00

Sangamo Therapeutics (NASDAQ:SGMO) had its price target raised by Barclays from $3.00 to $9.00 in a report released on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s price objective indicates a potential upside of 339.02% from the stock’s current price.

Several other equities research analysts have also recently issued reports on the stock. HC Wainwright lifted their target price on shares of Sangamo Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. StockNews.com began coverage on shares of Sangamo Therapeutics in a research report on Sunday, July 28th. They set a “sell” rating on the stock.

Sangamo Therapeutics Stock Down 4.7 %

Shares of SGMO opened at $2.05 on Thursday. Sangamo Therapeutics has a 52-week low of $0.30 and a 52-week high of $3.18. The firm’s fifty day moving average is $1.33 and its two-hundred day moving average is $0.86. The stock has a market cap of $427.67 million, a PE ratio of -2.73 and a beta of 1.10.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Meritage Portfolio Management lifted its position in Sangamo Therapeutics by 8.6% in the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 6,740 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its position in Sangamo Therapeutics by 61.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 23,650 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Sangamo Therapeutics by 55.4% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 38,850 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Sangamo Therapeutics by 5.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock valued at $956,000 after buying an additional 57,125 shares during the last quarter. Finally, XTX Topco Ltd lifted its position in Sangamo Therapeutics by 167.8% in the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 64,981 shares during the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.